...
首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.
【24h】

Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.

机译:从疑似肿瘤性脑膜炎的肺腺癌患者的脑脊液中检测上皮生长因子受体突变。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: : Neoplastic meningitis (NM) is a devastating neurological complication of cancer that needs to be diagnosed in the early stages of disease. Polymerase chain reaction detection of epithelial growth factor receptor (EGFR) mutations in cerebrospinal fluid (CSF), which are predictive markers for EGFR tyrosine kinase inhibitor therapy in lung cancer, might be important to diagnose and to treat NM in patients with lung cancer. In this study, we attempted to detect EGFR mutations in CSF and to compare EGFR status between CSF and primary or metastatic lesions in patients with lung adenocarcinoma suspected of NM. METHODS: : Twenty-nine patients with lung adenocarcinoma suspected of having NM underwent lumbar puncture. EGFR status of CSF was analyzed by direct DNA sequencing. EGFR mutations of primary or metastatic lesions (lymph nodes and bones) were analyzed in 20 cases. RESULTS: : EGFR mutations were detected in CSF of 13 (45%) of 29 patients. In 5 (31%) of 16 patients with negative CSF cytology, EGFR mutations were detected. In four patients, EGFR mutations were shown in CSF, but not in primary or metastatic lesions. Conversely, in two patients, EGFR mutations were shown in primary or metastatic lesions, but not in CSF despite positive CSF cytology. CONCLUSIONS: : EGFR mutations, suggesting the existence of malignant cells, were detected in CSF, even in patients with non-small cell lung cancer with negative cytological results. EGFR mutations in CSF do not always reflect the same status as in primary or metastatic lesions.
机译:背景:肿瘤性脑膜炎(NM)是一种破坏性的神经系统癌症并发症,需要在疾病的早期阶段进行诊断。聚合酶链反应检测脑脊液(CSF)中的上皮生长因子受体(EGFR)突变是肺癌EGFR酪氨酸激酶抑制剂治疗的预测标志物,对肺癌的诊断和治疗可能具有重要意义。在这项研究中,我们试图检测CSF中的EGFR突变,并比较CSF与怀疑为NM的肺腺癌患者的CSF与原发性或转移性病变之间的EGFR状态。方法:29例怀疑为NM的肺腺癌患者接受了腰穿。通过直接DNA测序分析了CSF的EGFR状态。分析20例原发或转移性病变(淋巴结和骨骼)的EGFR突变。结果:29例患者中有13例(45%)的CSF检测到EGFR突变。在CSF细胞学阴性的16例患者中,有5例(31%)检测到EGFR突变。在四名患者中,EGFR突变在CSF中显示,但在原发性或转移性病变中未显示。相反,在两名患者中,尽管CSF细胞学检查阳性,但在原发或转移灶中发现了EGFR突变,但在CSF中未发现。结论:即使在非小细胞肺癌细胞学结果阴性的脑脊液中,也发现了EGFR突变,表明存在恶性细胞。 CSF中的EGFR突变并不总是反映与原发或转移性病变相同的状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号